title: Listening to Provenge--what a costly cancer treatment says about future Medicare policy.
authors.affiliation: Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA.
authors.forename: James D
authors.initials: JD
authors.lastname: Chambers
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Neumann
mesh_terms: D019496:Cancer Vaccines / Q000191:economics / Q000627:therapeutic use*; D014487:Centers for Medicare and Medicaid Services, U.S.; D017277:Drug Approval / Q000458:organization & administration*; D016527:Drug Costs; D006291:Health Policy; D006801:Humans; D008297:Male; D006278:Medicare; D016345:Medicare Part B; D054524:Medicare Part D; D011471:Prostatic Neoplasms / Q000628:therapy*; D014020:Tissue Extracts / Q000191:economics / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T